About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Yawn !!!

is yesterdays share magazine

EiRx Therapeutics (ERX:AIM) Interims PTP: -0.9m (-0.9m) Divi: n/a (n/a)
Trials of the companys breast cancer product ERX3722 showed a 50% reduction in
tumour size, which it says endorses its decision to change its business model from
a research services company to a drug discoverer.
It discovered ERX3722 using its EnPad candidate screening technology and
believes this is capable of developing more products targeting different genes and
tumour types.
A share placing in September raised 500,000 but it is now looking for opportunities
such as grant funding, partnering deals with larger businesses and M&A
options to help it progress. Shares have been on a downward spiral for the last six
months but they should recover if it is successful in securing a deal.
■ Shares says: Needs a deal to help advance its technology.

Sounds Good

well we know they were in talks for a JV a good while back.. but dont know whats holding it all up

Nice write up PH

well we have already been aware they have been in negotiations for some time.. just wish we knew whats holding it all up

OSI webcast tomorrow should have news on the osi-027, as I understand this is the one that belongs to us

A bit of blue makes a change.

it does !! still need something soon me finks !!

Disappointing to say the least but life goes on at ERX.

These four kinases rejoin the panel of apoptosis targets currently subject to collaborative discussions with other parties.'

Contract Update

http://moneyam.uk-wire.com/cgi-bin/articles/200705251455062749X.html

This will be the big one, still accumulating.


19 September 2006

A 50% reduction in breast tumour volume size seen with Eirx lead molecule in
animal studies

'A reduction in tumour volume of 50% is seen by the National Cancer Institute in
America, and other leading authorities as being highly significant' said
Professor Tom Cotter, founder and CSO of EiRx. 'We are now in active
discussions with a developmental company to further develop this molecule and to
prepare it for a future phase 1 clinical trial.

Across the seven major markets, 443,000 women were estimated to have developed
breast cancer in 2004, with an estimated 112,000 dying from the disease. The
incidence is forecast to increase annually at an average rate of 3%. The size
of the market for breast cancer drugs is $6.2 billion; representing 17% of the
total spend of the cancer market.

sp coming back.

Plenty left.

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Left alone :-(

No still here driver ;)

smiler
Well it can't get any worse there must be some good news some where in ERX

Some good posts here chaps I am taking a look at the company, loving the South of Ireland is a big plus too.

All input welcomed unlike some here I like both postive and negative views please.

Have agreat day.

Second day of rises the sp is coming back strong to a more sensible level, after its fall.

might have known--as soon as I move on!!!

mp
Drivers tips theres post for you.